Classification criteria for the idiopathic inflammatory myopathies

Current Opinion in Rheumatology

Volumn 9, Issue 6, 1997, Pages 527-535

  Targoff, Ira N ^a   Miller, Frederick W ^b   Medsger Jr , Thomas A ^c   Oddis, Chester V ^c  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLASSIFICATION; DERMATOMYOSITIS; DISEASE CLASSIFICATION; HUMAN; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYOPATHY; MYOSITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RASH; REVIEW;

EID: 0030867050     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199711000-00008     Document Type: Review

References (60)

1. Bohan A, Peter JB: Polymyositis and dermatomyositis: parts 1 and 2. N Engl J Med 1975, 292:344-347,403-407.
2. Dalakas MC, Sivakumar K: The immunopathologic and Inflammatory differences between dermatomyositis, polymyositis and sporadic inclusion body myositis. Curr Opin Neurol 1996, 9:235-239.
3. Miller ': Classification and prognosis of Inflammatory muscle disease. Rheum Dis Clin North Am 1995, 20:811-826.
4. Tanimoto K, Nakano K, Kano S, Mori S, Ueki H, Nishitani H, Sato T, Kiuchi T, Ohashi Y: Classification criteria for polymyositis and dermatomyositis. J Rheumatol 1995, 22:668-674. A multicenter collaborative study of a new criteria set raises the issue of using clinical signs of systemic inflammatory illness and muscle tenderness as diagnostic criteria in IIMs. This study illustrates the importance of the comparison group in assessing the sensitivity and specificity of criteria.
5. Askanas V, Engel WK: New advances in the understanding of sporadic inclusion-body myositis and hereditary inclusion-body myopathies. Curr Opin Rheumatol 1995, 7:486-496.
6. Griggs RC, Askanas VA, DiMauro S, Engel A, Karpati G, Mondell JR, Rowland LP: Inclusion body myositis and myopathies. Ann Neurol 1995, 38:705-713.
7. Fonseca GA, Baca S, Altman RD: Acute myositis and dermatitis as the initial presentation of sarcoidosis. Clin Exp Rheumatol 1993, 11:553-556.
8. Kaufman LD, Kephart GM, Seidman RJ, Buhner D, Quarfordt I, Nassberger L, Gleich GJ: The spectrum of eosinophilic myositis: clinical and immunopathogenic studies of three patients, and review of the literature. Arthritis Rheum 1993, 36:1014-1024.
9. Goebels N, Michaelis D, Engelhardt M, Huber S, Bender A, Pongratz D, Johnson MA, Wekerle H, Tschopp J, Jenne D, Hohlfeld R: Differential expression of perform in muscle-Infiltrating T cells in polymyositis and dermatomyositis. J Clin invest 1996, 97:2905-2910. Another demonstration of important pathogenetic differences between PM and DM. The distribution of perforin in the muscle of patients with PM, as contrasted with DM, indicates an active role in muscle damage in PM.
10. Crowson AN, Magro CM: The role of microvascular injury in the pathogenesis of cutaneous lesions of dermatomyositis. Hum Pathol 1996, 27:15-19. Several studies over the past decade have shown that the membrane-attack complex of complement is deposited in small muscle blood vessels in DM, especially juvenile DM but also adult DM. This is felt to be a major mechanism of muscle injury in DM. This study demonstrates that this complex may also be involved in the cutaneous lesions of DM.
11. Calabrese LH, Chou SM: Inclusion body myositis. Rheum Dis Clin North Am 1994, 20:955-972.
12. Carpenter S: Inclusion body myositis: a review. J Neuropathol Exp Neurol 1996, 55:1105-1114.
13. Amato AA, Grondeth GS, Jackson CE, Wolfe GI, Katz JS, Bryan WW, Barohn RJ: Inclusion body myositis: clinical and pathological boundaries. Ann Neurol 1996, 40:581-586. This study emphasizes that establishing the diagnosis of IBM is sometimes difficult early in disease. Patients who later prove to have IBM may not show the signs on initial biopsy.
14. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW: A new approach to the classification of idiopathic Inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 1991, 70:360-374.
15. Joffe MM, Love LA, Leff RL, Fraser DD, Targoff IN, Nicks JE, Plotz PH, Miller FW: Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993, 94:378-387.
16. Fries JF, Hochberg MC, Medsger TA Jr, Hunder GG, Bombardier C, and the American College of Rheumatology Diagnostic and Therapeutic Criteria Committee: Criteria for rheumatic disease: different types and different functions. Arthritis Rheum 1994, 37:454-562.
17. Medsger TA Jr, Dawson WN Jr, Masi AT: The epidemiology of polymyositis. Am J Med 1970, 48:715-723.
18. DeVere R, Bradley WG: Polymyositis: its presentation, morbidity and mortality. Brain 1975, 98:637-666.
19. Fleckenstein JL, Reimers CD: Inflammatory myopathies: radiologic evaluation. Radiol Clin North Am 1996, 34:427-439.
20. Oddis CV, Medsger TA Jr: Inflammatory myopathies. Clin Rheumatol 1995, 9:497-514.
21. Hochberg MC: Epidemiology of polymyositis/dermatomyositis. Mt Sinai J Med 1988, 55:447-452.
22. Subcommittee for Scleroderma Criteria of the American Rheumatism Association, Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23:581-590.
23. Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, Lewis CW, Pariser DM, Skouge JW, Webster SB, et al.: Guidelines of care for dermatomyositis: American Academy of Dermatology. J Am Acad Dermatol 1996, 34:824-829. A summary of diagnosis and treatment in outline form that is useful for rheumatologists in their recommendations regarding the cutaneous aspects of DM.
24. Dalakas M: Clinical, immunopathologic, and therapeutic considerations of inflammatory myopathies. Clin Neuropharmacol 1992, 15:327-351.
25. Targoff IN: Immune manifestations of inflammatory muscle disease. Rheum Dis Clin North Am 1994, 20:857-880.
26. Vazquez-Abad D, Rothfield NF: Sensitivity and specificity of anti-Jo-1 antibodies in autoimmune diseases with myositis. Arthritis Rheum 1996, 39:292-296. This study confirms the very high specificity of anti-Jo-1 antibody for PM/DM compared with other connective tissue diseases.
27. Seelig HP, Moosbrugger IU, Ehrfeld H, Fink T, Renz M, Genth E: The major dermatomyositis-specific Mi-2 autoantigen is a presumed helicase involved in transcriptional activation. Arthritis Rheum 1995, 38:1389-1399. Excellent study that combines the molecular analysis of the Mi-2 antigen (later found to be one of at least two forms of Mi-2, this one labeled Mi-2β) with the use of a recombinant fragment of the molecule to examine the frequency and disease specificity of the autoantibody in a large population of patients.
28. Rider LG, Miller FW: Laboratory evaluation of the inflammatory myopathies. Clin Diagn Lab Immunol 1995, 2:1-9.
29. Oddis CV, Okano Y, Rudert WA, Trucco M, Duquesnoy RJ, Medsger TA Jr: Serum autoantibody to the nucleolar antigen PM-Scl: clinical and immunogenetic association. Arthritis Rheum 1992, 35:1211-1217.
30. Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW, Jarzabek-Chorzelska M, Targoff IN, Blaszczyk-Kostanecka M, Jablonska S: Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997, 40:1257-1266. This study analyzed the clinical, serologic, and immunogenetic correlations in a group of Polish patients with IIM.
31. Schnitz W, Taylor-Albert E, Targoff IN, Reichlin M, Scofield RH: Anti PM/Scl autoantibodies in patients without clinical polymyositis or scleroderma. J Rheumatol 1996, 23:1729-1733. Of 55 patients with the anti-PM-Scl antibody, five were identified without PM/DM, systemic sclerosis, or an overlap syndrome. Thus 10% of this institution's anti-PM-Scl-positive patients had an undifferentiated connective tissue disease.
32. Jablonska S, Chorzelski TP, Blaszczyk M, Jarzabek-Chorzelska M, Kumar V, Beutner EH: Scleroderma/polymyositis overlap syndromes and their immunologic markers. Dermatology 1993, 10:457-472.
33. Cambridge G, Ovadia E, Isenberg DA, Dubowitz V, Sperling J, Sperling R: Juvenile dermatomyositis: serial studies of circulating autoantibodies to a 56kD nuclear protein. Clin Exp Rheumatol 1994, 12:451-457.
34. Feist E, Dorner T, Kuckelkorn U, Schmidtke G, Micheel B, Hiepe F, Burmester GR, Kloetzel PM: Proteasome alpha-type subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus. J Exp Med 1996, 184:1313-1318. Sixty-two percent of myositis and 58% of lupus patients were shown to have anti-proteasome antibodies. A description of these antibodies is of great interest, but they are not yet able to provide diagnostic information beyond demonstration of autoimmunity.
35. Yamanishi Y, Maeda H Katayama S, Ishioka S, Yamakido M: Scleroderma-polymyositis overlap syndrome associated with anti-Ku antibody and rimmed vacuole formation. J Rheumatol 1996, 23:1991-1994.
36. Uthman I, Vazquez-Abad D, Senecal JL: Distinctive features of idiopathic inflammatory myopathies in French Canadians. Semin Arthritis Rheum 1996, 26:447-458. The clinical picture of myositis was examined in 30 patients from a population that had not previously been studied. Two patients were found to have autoantibodies to nuclear pore complexes, but surprisingly, none had anti-Jo-1. The 10-year survival rate was 85%.
37. Perurena O, Targoff IN, Bobele G, Parke J, Hussain F: Lack of myositis-specific autoantibodies (MSA) in Duchenne muscular dystrophy [abstract]. Ann Neurol 1993.
38. Mierau R, Dick T, Bartz-Bazzanella P, Keler E, Albert ED, Genth E: Strong association of dermatomyositis-specific Mi-2 autoantibodies with a tryptophan at position 9 of the HLA-DR beta chain. Arthritis Rheum 1996, 39:868-876. Although the association of anti-Mi-2 with HLA-DR7 is known, this study examined the immunogenetics of anti-Mi-2 in greater detail. Thirty-one percent of the patients with anti-Mi-2 were homozygous for DR7, 100% had a tryptophan at position 9 of DRβ, with 81% homozygous for this finding. Of additional interest is the detailed examination of the clinical findings in the anti-Mi-2 subgroup of DM.
39. Gelpi C, Kanterewicz E, Gratacos J, Targoff IN, Rodriguez-Sanchez JL: Coexistence of two antisynthetases in a patient with the antisynthetase syndrome. Arthritis Rheum 1996, 39:692-697. This description of the first patient found to have both anti-Jo-1 and another antisynthetase antibodies serves to highlight how rare this finding is.
40. Hirakata M, Nakamura K, Okano T, Suwa A, Inada S, Akzuki M, Hardin JA: Anti-alanyl-tRNA synthetase (PL-12) antibodies are associated with interstitial lung disease in Japanese patients. Arthritis Rheum 1995, 38:S321.
41. Friedman AW, Targoff IN, Arnett FC: Interstitial lung disease with autoantibodies, against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 1996, 26:459-467. Antisynthetases were first described in PM/DM, but ILD is also very common in such patients and is often a more significant clinical problem. This study focused on the fact that some antisynthetase patients do not show clinical signs of myositis. All patients had a picture otherwise compatible with the antisynthetase syndrome. Anti-L-12 was the most common antisynthetase in this group.
42. Venables Pj: Polymyositis-associated overlap syndromes. Br J Rheumatol 1996, 35:305-306.
43. Fraser DD, Frank JA, Dalakas MC, Miller FW, Hicks JE, Plotz PH: Magnetic resonance imaging in the idiopathic inflammatory myopathies. J Rheumatol 1991, 18:1693-1700.
44. Reimers CD, Schedel H, Fleckenstein JL, Nagele M, Witt T, Pongratz DE, Vogl TJ: Magnetic resonance imaging of skeletal muscles in idiopathic inflammatory myopathies of adults. J Neurol 1994, 241:306-314.
45. Park JH, Vital TL, Ryder NM, Hernanz-Schulman M, Partain CL, Price RR, Olsen NJ: Magnetic resonance imaging and P-31 magnetic resonance spectroscopy provide unique quantitative data useful In the longitudinal management of patients with dermatomyositis. Arthritis Rheum 1994, 376:736-746.
46. Park JH, Olsen NJ, King LE, Vital T, Buse R, Kari S, Hernanz-Schulman M, Price RR: Use of magnetic resonance imaging and P-31 magnetic resonance spectroscopy to detect and quantify muscle dysfunction in the amyopathic and myopathic variants of dermatomyositis. Arthritis Rheum 1995, 38:68-77.
47. Stonecipher MR, Jorizzo JL, Monu J, Walker F, Sutej PG: Dermatomyositis with normal muscle enzyme concentrations: a single-blind study of the diagnostic value of magnetic resonance imaging and ultrasound. Arth Dermatol 1994, 130:1294-1299.
48. Fujino H, Kobayashi T, Goto I, Onitsuka H: Magnetic resonance imaging of the muscles in patients with polymyositis and dermatomyositis. Muscle Nerve 1991, 14:716-720.
49. Buchpiguel CA, Roizemblatt S, Pastor EH, Hironaka FH, Cossermellil W: Cardiac and skeletal muscle scintigraphy in dermato- and polymyositis: clinical implications. Eur J Nucl Med 1996, 23:199-203.
50. Miller FW: Inflammatory myopathies: polymyositis, dermatomyositis, and related conditions. In Arthritis and Allied Conditions: A Textbook of Rheumatology. Edited by Koopman W. Baltimore: Williams & Wilkins; 1996:1407-1432.
51. Zuber M: Tanimoto's classification and diagnostic criteria for polymyositis and dermatomyositis do not recognize the variant of amyopathic dermatomyositis. J Rheumatol 1996, 23:191.
52. Bohan A, Peter JB, Bowman RL, Pearson CM: A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 1977, 56:255-286.
53. Henriksson KG, Sandstedt P: Polymyositis-treatment and prognosis. Acta Neurol Scand 1982, 65:280-300.
54. Hoffman GS, Franck WA, Raddatz DA: Presentation, treatment and prognosis of idiopathic inflamatory muscle disease in a rural hospital. Am J Med 1983, 75:433-438.
55. Benbassat J, Gefel D, Larholt K, Sukenik S, Morgenstern V, Zlotnick A: Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninety-two cases. Arthritis Rheum 1985, 28:249-255.
56. Tymms KE, Webb J: Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol 1985, 12:1140-1148.
57. Hochberg MC, Feldman D, Stevens MB: Adult onset polymyositis/dermatomyosrtis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Semin Arthritis Rheum 1986, 15:168-178.
58. Oddis CV, Conte CG, Steen VD, Medgser TA: Incidence of polymyositis-dermatomyositis: a 20 year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol 1990, 17:1329-1334.
59. Prasad ML, Sarkar C, Roy S: Idiopathic inflammatory myopathy: clinicopathologic observations in the Indian population. Br J Rheumatol 1992, 31:835-839.
60. Koh ET, Scow A, Ong B: Adult onset polymyositis/dermatomyositis: clinical and laboratory features and treatment response in 75 patients. Ann Rheum Dis 1993, 52:857-861.